Acute and chronic effect of nifedipine in primary aldosteronism

G. Carpenè, S. Rocco, G. Opocher, F. Mantero

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Since calcium entry blocker drugs can interfere with aldosterone secretion in vitro, a similar effect in vivo, in man, has been suggested and partially confirmed. The data available in primary aldosteronism are more controversial. Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA). On 2 different days, 10 mg of nifedipine or placebo were given sublingually to the patients and blood pressure and heart rate were recorded every 5 min. for 60 min. Plasma aldosterone, cortisol, PRA and serum K were measured at 0, 30 and 60 min. 5 patients with IHA and 6 with APA received nifedipine 20 mg per os bid for 3 months; the same parameters were evaluated on days 0, 30, 60 and 90; urinary aldosterone was measured on days 0, 30, 60 and 90. BP decreased in both groups both after acute and chronic administration of nifedipine. Plasma aldosterone showed a similar trend either after acute nifedipine or placebo; however, during chronic treatment it was slightly decreased in IHA patients. Cortisol, PRA, urinary aldosterone and K+ remained unchanged. In conclusion, nifedipine is an effective antihypertensive agent also in primary aldosteronism; its aldosterone inhibiting properties are minimal and seem to be present only during long-term therapy in IHA.

Original languageEnglish
Pages (from-to)1263-1272
Number of pages10
JournalClinical and Experimental Hypertension
VolumeA11
Issue number7
DOIs
Publication statusPublished - 1989

Fingerprint

Hyperaldosteronism
Nifedipine
Aldosterone
Adenoma
Hydrocortisone
Placebos
Antihypertensive Agents
Heart Rate
Blood Pressure
Calcium
Therapeutics
Serum

Keywords

  • Nifedipine
  • Primary aldosteronism

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology

Cite this

Acute and chronic effect of nifedipine in primary aldosteronism. / Carpenè, G.; Rocco, S.; Opocher, G.; Mantero, F.

In: Clinical and Experimental Hypertension, Vol. A11, No. 7, 1989, p. 1263-1272.

Research output: Contribution to journalArticle

Carpenè, G. ; Rocco, S. ; Opocher, G. ; Mantero, F. / Acute and chronic effect of nifedipine in primary aldosteronism. In: Clinical and Experimental Hypertension. 1989 ; Vol. A11, No. 7. pp. 1263-1272.
@article{1d24476b8c074798ab66af9c470537f2,
title = "Acute and chronic effect of nifedipine in primary aldosteronism",
abstract = "Since calcium entry blocker drugs can interfere with aldosterone secretion in vitro, a similar effect in vivo, in man, has been suggested and partially confirmed. The data available in primary aldosteronism are more controversial. Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA). On 2 different days, 10 mg of nifedipine or placebo were given sublingually to the patients and blood pressure and heart rate were recorded every 5 min. for 60 min. Plasma aldosterone, cortisol, PRA and serum K were measured at 0, 30 and 60 min. 5 patients with IHA and 6 with APA received nifedipine 20 mg per os bid for 3 months; the same parameters were evaluated on days 0, 30, 60 and 90; urinary aldosterone was measured on days 0, 30, 60 and 90. BP decreased in both groups both after acute and chronic administration of nifedipine. Plasma aldosterone showed a similar trend either after acute nifedipine or placebo; however, during chronic treatment it was slightly decreased in IHA patients. Cortisol, PRA, urinary aldosterone and K+ remained unchanged. In conclusion, nifedipine is an effective antihypertensive agent also in primary aldosteronism; its aldosterone inhibiting properties are minimal and seem to be present only during long-term therapy in IHA.",
keywords = "Nifedipine, Primary aldosteronism",
author = "G. Carpen{\`e} and S. Rocco and G. Opocher and F. Mantero",
year = "1989",
doi = "10.3109/10641968909038169",
language = "English",
volume = "A11",
pages = "1263--1272",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Acute and chronic effect of nifedipine in primary aldosteronism

AU - Carpenè, G.

AU - Rocco, S.

AU - Opocher, G.

AU - Mantero, F.

PY - 1989

Y1 - 1989

N2 - Since calcium entry blocker drugs can interfere with aldosterone secretion in vitro, a similar effect in vivo, in man, has been suggested and partially confirmed. The data available in primary aldosteronism are more controversial. Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA). On 2 different days, 10 mg of nifedipine or placebo were given sublingually to the patients and blood pressure and heart rate were recorded every 5 min. for 60 min. Plasma aldosterone, cortisol, PRA and serum K were measured at 0, 30 and 60 min. 5 patients with IHA and 6 with APA received nifedipine 20 mg per os bid for 3 months; the same parameters were evaluated on days 0, 30, 60 and 90; urinary aldosterone was measured on days 0, 30, 60 and 90. BP decreased in both groups both after acute and chronic administration of nifedipine. Plasma aldosterone showed a similar trend either after acute nifedipine or placebo; however, during chronic treatment it was slightly decreased in IHA patients. Cortisol, PRA, urinary aldosterone and K+ remained unchanged. In conclusion, nifedipine is an effective antihypertensive agent also in primary aldosteronism; its aldosterone inhibiting properties are minimal and seem to be present only during long-term therapy in IHA.

AB - Since calcium entry blocker drugs can interfere with aldosterone secretion in vitro, a similar effect in vivo, in man, has been suggested and partially confirmed. The data available in primary aldosteronism are more controversial. Therefore, we have studied the acute and chronic effect of nifedipine in 7 patients with idiopathic hyperaldosteronism (IHA) and 8 with aldosterone producing adenoma (APA). On 2 different days, 10 mg of nifedipine or placebo were given sublingually to the patients and blood pressure and heart rate were recorded every 5 min. for 60 min. Plasma aldosterone, cortisol, PRA and serum K were measured at 0, 30 and 60 min. 5 patients with IHA and 6 with APA received nifedipine 20 mg per os bid for 3 months; the same parameters were evaluated on days 0, 30, 60 and 90; urinary aldosterone was measured on days 0, 30, 60 and 90. BP decreased in both groups both after acute and chronic administration of nifedipine. Plasma aldosterone showed a similar trend either after acute nifedipine or placebo; however, during chronic treatment it was slightly decreased in IHA patients. Cortisol, PRA, urinary aldosterone and K+ remained unchanged. In conclusion, nifedipine is an effective antihypertensive agent also in primary aldosteronism; its aldosterone inhibiting properties are minimal and seem to be present only during long-term therapy in IHA.

KW - Nifedipine

KW - Primary aldosteronism

UR - http://www.scopus.com/inward/record.url?scp=0024465939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024465939&partnerID=8YFLogxK

U2 - 10.3109/10641968909038169

DO - 10.3109/10641968909038169

M3 - Article

VL - A11

SP - 1263

EP - 1272

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 7

ER -